Prevention and treatment of amyloidogenic diseases
a technology of amyloidogenic diseases and amyloid aggregation, applied in the field of compositions, can solve the problem of not being immunologically available to the immune system
Inactive Publication Date: 2009-11-19
ELAN PHRMA INT LTD
View PDF81 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
"The present invention is about pharmaceutical compositions and methods for treating amyloid diseases by inducing an immune response against the amyloid components in a patient. The compositions include an agent that is effective in inducing an immune response against the amyloid component. The agent can be a peptide, a protein, an excipient, an adjuvant, or a combination of these. The method involves giving the patient a dosage of the effective agent to produce an immunological response against the amyloid component. The invention also includes a method of determining the prognosis of a patient undergoing treatment for an amyloid disorder by measuring the serum amount of immunoreactivity against the amyloid component. The invention also includes a method of passive immunization for preventing or treating amyloid diseases by giving the patient an effective dosage of an antibody that specifically binds to the amyloid component."
Problems solved by technology
When such fragments are formed, such as by proteolytic cleavage, epitopes may be revealed that are not present on the precursor and are therefore not immunologically available to the immune system when the fragment is a part of the precursor protein.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
examples
I. Prophylactic Efficacy of Aβ Against Alzheimer's Disease (AD)
[0226]These examples describe administration of Aβ42 peptide to transgenic mice overexpressing APP with a mutation at position 717 (APP717→F) that predisposes them to develop Alzheimer's-like neuropathology. Production and characteristics of these mice (PDAPP mice) is described in Games et al., Nature, supra. These animals, in their heterozygote form, begin to deposit Aβ at six months of age forward. By fifteen months of age they exhibit levels of Aβ deposition equivalent to that seen in Alzheimer's disease. PDAPP mice were injected with aggregated Aβ42 (aggregated Aβ42) or phosphate buffered saline. Aggregated Aβ42 was chosen because of its ability to induce antibodies to multiple epitopes of Aβ.
[0227]A. Methods
[0228]1. Source of Mice
[0229]Thirty PDAPP heterogenic female mice were randomly divided into the following groups: 10 mice for injection with aggregated Aβ42 (one died in transit), 5 mice to be injected with PBS / ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| diameter | aaaaa | aaaaa |
| diameter | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
Login to View More
Abstract
Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
Description
[0001]This is a continuation of pending U.S. application Ser. No. 11 / 842,046, filed on Aug. 20, 2007, which is a continuation of U.S. application Ser. No. 09 / 724,575, filed on Nov. 28, 2000, which is a continuation of U.S. application Ser. No. 09 / 585,817, filed on Jun. 1, 2000, and issued as U.S. Pat. No. 6,923,964, which claims the benefit of U.S. Provisional Application No. 60 / 137,010, filed Jun. 1, 1999, which is hereby incorporated herein in its entirety.FIELD OF THE INVENTION[0002]The invention relates to compositions and methods of treatment of amyloid-related conditions in humans and other mammalian vertebrates.BACKGROUND OF THE INVENTION[0003]Amyloidosis is a general term that describes a number of diseases characterized by extracellular deposition of protein fibrils, which form numerous “amyloid deposits,” which may occur in localized sites or systemically. The fibrillar composition of these deposits is an identifying characteristic for the various forms of amyloid disease....
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K39/00A61K39/02A61P35/00A61P37/04A61K38/00C12N15/09A61K39/39A61K39/44A61K45/08A61K47/48A61K48/00A61P1/04A61P3/00A61P17/00A61P17/06A61P19/00A61P19/02A61P25/28A61P29/00A61P37/00A61P43/00C07K16/18G01N33/68
CPCA61K39/0007A61K2039/505A61K2039/55505A61K2039/55566A61K2039/55572G01N2800/2821A61K2039/6037C07K16/18C07K2317/77G01N33/6896G01N2800/2814A61K2039/55577A61P1/04A61P17/00A61P17/06A61P19/00A61P19/02A61P25/28A61P29/00A61P3/00A61P31/00A61P35/00A61P37/00A61P37/02A61P37/04A61P43/00A61P7/04A61P9/10A61P3/10A61K38/00
Inventor SCHENK, DALE B.
Owner ELAN PHRMA INT LTD